Clinical Application of Doxazosin Mesylate in Female Overactive Bladder
-
摘要:
目的 研究甲磺酸多沙唑嗪应用于合并排尿期症状的女性膀胱过度活动症（OAB）患者的临床治疗作用。 方法 回顾性分析2021年6月至12月因下尿路症状（LUTS）于昆明医科大学第二附属医院泌尿外科门诊就诊，诊断为OAB同时合并排尿期症状的68例女性患者，其中36例予甲磺酸多沙唑嗪联合琥珀酸索利那新片治疗，为治疗组；32例予琥珀酸索利那新片治疗，为对照组，2组均治疗12周后，使用美国泌尿学会症状评分（AUAss）、膀胱过度活动症症状评分（OABSS）、生活质量（QOL）评分比较治疗前后的症状，评估疗效。 结果 68例OAB患者治疗12周后，治疗组和对照组的OABSS、AUAss、QOL评分较术前均明显改善，差异有统计学意义（P < 0.05）。实验组和对照组用药后AUAss评分，差异有统计学意义（P < 0.05）。 结论 甲磺酸多沙唑嗪联合琥珀酸索立纳新应用于合并排尿期症状的女性OAB患者，可改善LUTS，提高生活质量。 Abstract:Objective To study the clinical therapeutic effect of doxazosin mesylate on female patients with overactive bladder （OAB） complicated with micturition symptoms. Methods A retrospective analysis was made of 68 female patients who were diagnosed with OAB and complicated with micturition symptoms in the Outpatient Department of Urology of the Second Affiliated Hospital of Kunming Medical University from June to December 2021 due to lower urinary tract symptoms （LUTS）. Among them, 36 cases were treated with doxazosin mesylate combined with solinacin succinate tablets as the treatment group; 32 cases were treated with solinacin succinate tablets as the control group. After 12 weeks of the treatment, the symptoms before and after the treatment were compared using American Urological Association symptom score （AUAss）, overactive bladder symptom score （OABSS） and quality of life （QOL） score. Results After 12 weeks of the treatment, the scores of OABSS, AUAss and QOL in the treatment group and the control group were significantly improved compared with those before the treatment （P < 0.05）. There was significant difference in AUAss between the treatment group and the control group （P < 0.05）. Conclusion Doxazosin mesylate combined with sorinaxin succinate tablets can improve lower urinary tract symptoms and quality of life in female patients with OAB complicated with micturition symptoms. -
Key words:
- Doxazosin mesylate /
- Female overactive bladder /
- Micturition symptoms /
- Medication.
-
表 1 2组基线资料比较
Table 1. Comparison of the baseline characteristics between the two groups
比较项目 治疗组 对照组 t/z P 例数（n） 36 32 年龄（$\bar x \pm s $，岁） 52.72 ± 14.76 45.78 ± 17.59 1.77 0.082 病程[M（P25，P75）月] 28（24，36） 26（19，36） 0.88 0.381 
下载: 导出CSV
表 2 2组治疗前后AUAss比较[（
$\bar x \pm s $ ），分]Table 2. Comparison of the AUAss between the two groups before and after treatment [（
$\bar x \pm s $ ），points]分组 治疗前 治疗后 t P 治疗组 19.75 ± 3.37 8.97 ± 1.84 26.51 < 0.001* 对照组 19.00 ± 2.90 15.38 ± 2.70 13.70 < 0.001* t 0.98 11.53 P 0.331 < 0.001* *P < 0.05。
下载: 导出CSV
表 3 2组治疗前后OABSS比较[（
$\bar x \pm s $ ），分]Table 3. Comparison of the OABSS between the two groups before and after treatment [（
$\bar x \pm s $ ），points]分组 治疗前 治疗后 t P 治疗组 9.83 ± 1.93 3.67 ± 0.96 21.16 < 0.001* 对照组 10.53 ± 1.44 3.44 ± 1.13 26.59 < 0.001* t 1.67 0.90 P 0.099 0.369 *P < 0.05。
下载: 导出CSV
表 4 2组治疗前后QOL评分比较[（
$\bar x \pm s $ ），分]Table 4. Comparison of the QOL score between the two groups before and after treatment [（
$\bar x \pm s $ ），points]分组 治疗前 治疗后 t P 治疗组 5.39 ± 0.64 1.83 ± 0.77 19.74 < 0.001* 对照组 5.31 ± 0.69 1.59 ± 0.66 24.71 < 0.001* t 0.47 1.36 P 0.639 0.179 *P < 0.05。
下载: 导出CSV
-
[1] Haylen B T,De Ridder D,Freeman R M,et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction[J]. Neurourology And Urodynamics,2010,29(1):4-20. doi: 10.1002/nau.20798 [2] 郭应碌. 中国泌尿外科和男科疾病诊断治疗指南[M]. 北京: 科学出版社, 2020: 330-341. [3] Wang Yuliang,Xu Kexin,Hu Hao,et al. Prevalence,risk factors,and impact on health related quality of life of overactive bladder in China[J]. Neurourology and Urodynamics,2011,30(8):1448-1455. doi: 10.1002/nau.21072 [4] GAMé X,PHé V. Pathophysiology of overactive bladder[J]. Progres En Urologie,2020,30(14):873-879. doi: 10.1016/j.purol.2020.08.003 [5] Andersson K E,Pehrson R. CNS involvement in overactive bladder:Pathophysiology and opportunities for pharmacological intervention[J]. Drugs,2003,63(23):2595-2611. doi: 10.2165/00003495-200363230-00003 [6] De Groat W C. Integrative control of the lower urinary tract:Preclinical perspective[J]. British Journal of Pharmacology,2006,147(S2):25-40. doi: 10.1038/sj.bjp.0706604 [7] Andersson K E. Storage and voiding symptoms: Pathophysiologic aspects [J]. Urology, 2003, 62（Suppl 5B）: 3-10. [8] Lai H,Gardner V,Vetter J,et al. Correlation between psychological stress levels and the severity of overactive bladder symptoms[J]. BMC Urology,2015,15(1):14. doi: 10.1186/s12894-015-0009-6 [9] 高红英,吴玉斌. 膀胱过度活动症诊治进展[J]. 中国实用儿科杂志,2016,31(5):379-385. [10] Vij M,Robinson D,Cardozo L. Overactive bladder:Diagnosis and treatment[J]. Womens Health,2010,6(2):297-310. [11] Robinson D,Cardozo L. Overactive bladder:Diagnosis and management[J]. Maturitas,2011,71(2):188-193. [12] Gamé X,Phé V. Treatment for refractory non-neurogenic overactive bladder[J]. Progres En Urologie,2011,30(14):920-930. [13] Schwinn D A,Roehrborn C G. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms[J]. International Journal of Urology,2008,15(3):193-199. doi: 10.1111/j.1442-2042.2007.01956.x -
